Micronized Palmitoylethanolamide-Polydatin Reduces the Painful Symptomatology in Patients with Interstitial Cystitis/Bladder Pain Syndrome
Open-label, no control groupHumansWith polydatin
This study tested palmitoylethanolamide together with polydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Open-label, no control group
- Subjects
- 32 patients with interstitial cystitis or bladder pain syndrome not helped by conventional treatment, at two centres
- Dose used in the study
- Oral micronised palmitoylethanolamide with polydatin; dose not in the abstract
- Duration
- 6 months
- What was measured
- Bladder pain VAS; O'Leary-Sant symptom and problem indexes; Pelvic Pain and Urgency/Frequency scale; voiding diary; bladder capacity in 32 patients over 6 months
What the authors reported
Pain fell progressively over 6 months (p < 0.0001), with lower symptom and problem scores and lower urinary frequency. Bladder capacity improved slightly but not significantly.
Limits of this study
Open label with no control group, 32 patients. One author is affiliated with Innovative Statistical Research, Padua. The authors declare no conflicts of interest.
Source
PubMed 31828153 · doi:10.1155/2019/9828397
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.